Loading stock data…
Septerna (SEPN)
$37.37+0.62 (+1.69%)
Market ClosedLast close Sep 8
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Septerna, Inc. in the Healthcare sector is trading at $37.37 with a market capitalization of $1.6B. Wall Street consensus targets $54.22 (9 analysts), implying a +45.1% move over the next 12 months. The stock is currently 27% below its 52-week high of $51.10, remaining 25.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.52M↑ | $24.12M↑ | $21.50M↑ | $119,000↓ | $219,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.30M↑ | -$16.02M↓ | -$9.89M↑ | -$28.98M↓ | -$25.91M |
| Net Income | -$8.64M↑ | -$10.74M↓ | $8.17M↑ | -$24.84M↓ | -$21.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R P...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.52%
Volume
Today's trading volume
309,699
Recent News
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.
Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim began coverage of SEPN with a Buy rating and assigned the company a $52 price target. In […]